David Mesher

6.7k citations

52 papers · 3.2k indexed · 2 hit papers · h-index 26

Impact in

Immunology and Allergy top 1%
- Food Allergy and Anaphylaxis Research
- Allergic Rhinitis and Sensitization
Epidemiology top 2%
- Cervical Cancer and HPV Research
- Hepatitis B Virus Studies

Papers in ⓘ

Epidemiology 36
- Cervical Cancer and HPV Research 33
- Hepatitis B Virus Studies 11
Surgery 28
- Genital Health and Disease 25

Co-authors: Peter Sasieni (15 shared papers)Jack Cuzick (12 shared papers)Kate Soldan (19 shared papers)D M Parkin (1 shared paper)Daniel M. Berney (5 shared papers)Peter T. Scardino (2 shared papers)Gabrielle Fisher (3 shared papers)Louise Cadman (6 shared papers)
Journals: British Journal of Cancer (7 papers)Sexually Transmitted Infections (7 papers)Vaccine (3 papers)Eurosurveillance (3 papers)International Journal of Cancer (3 papers)
Partner nations: United Kingdom United States Italy

In The Last Decade

David Mesher

50 papers receiving 3.1k citations

Hit Papers

align trajectories log scale

Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study 2011 · 548 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2011 The Lancet Oncology
2008 Journal of Allergy and Clinical Immunology

Peers

Countries citing papers authored by David Mesher

Since Specialization

Citations

This map shows the geographic impact of David Mesher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Mesher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Mesher more than expected).

Fields of papers citing papers by David Mesher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Mesher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Mesher. The network helps show where David Mesher may publish in the future.

Co-authors

The 25 scholars most cited alongside David Mesher, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David Mesher Line = papers co-authored together David Mesher links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 52 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study The Lancet Oncology ·Jack Cuzick, Gregory P. Swanson, Gabrielle Fisher, Arthur R. Brothman, Daniel M. Berney, Julia Reid, David Mesher, V. O. Speights, Elzbieta Stankiewicz, Christopher S. Foster, Henrik Møller, Peter T. Scardino, Jorja D Warren, Jimmy Park, Adib Younus, Darl D. Flake, Susanne Wagner, Alexander Gutin, Jerry S. Lanchbury, Steven Stone Hit paper breakdown →	2011	548
2	Early consumption of peanuts in infancy is associated with a low prevalence of peanut allergy Journal of Allergy and Clinical Immunology ·George Du Toit, Yitzhak Katz, Peter Sasieni, David Mesher, Soheila J. Maleki, Helen R. Fisher, Adam Fox, Victor Turcanu, Tal Amir, Galia Zadik-Mnuhin, Adi Cohen, Irit Livne, Gideon Lack Hit paper breakdown →	2008	541
3	Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort British Journal of Cancer ·(unknown), Jack Cuzick, Daniel M. Berney, Gabrielle Fisher, David Mesher, Henrik Møller, J. Reid, M. D. Perry, J. Park, Adib Younus, Alexander Gutin, Christopher S. Foster, Peter T. Scardino, J. S. Lanchbury, Steven Stone	2012	267
4	13. Cancers attributable to solar (ultraviolet) radiation exposure in the UK in 2010 British Journal of Cancer ·D M Parkin, David Mesher, Peter Sasieni	2011	174
5	Comparing the performance of six human papillomavirus tests in a screening population British Journal of Cancer ·Jack Cuzick, Louise Cadman, David Mesher, Janet Austin, Lesley Ashdown-Barr, Linda Ho, George Terry, Stuart Liddle, Catherine Wright, D. Lyons, Anne Szarewski	2013	160
6	HPV self-sampling as an alternative strategy in non-attenders for cervical screening – a randomised controlled trial British Journal of Cancer ·Anne Szarewski, Louise Cadman, David Mesher, Janet Austin, Lesley Ashdown-Barr, R Edwards, D. Lyons, J Walker, J Christison, Alison Frater, Jo Waller	2011	130
7	Comparison of Seven Tests for High-Grade Cervical Intraepithelial Neoplasia in Women with Abnormal Smears: the Predictors 2 Study Journal of Clinical Microbiology ·Anne Szarewski, David Mesher, Louise Cadman, Janet Austin, Lesley Ashdown-Barr, Linda Ho, George Terry, Stuart Liddle, Martin Young, Mark H. Stoler, Julie McCarthy, C. A. Wright, Christine Bergeron, W. P. Soutter, Deirdre Lyons, Jack Cuzick	2012	130
8	A Surveillance Model for Skin Cancer in Organ Transplant Recipients: A 22-Year Prospective Study in an Ethnically Diverse Population American Journal of Transplantation ·Catherine Harwood, David Mesher, J.M. McGregor, L. Mitchell, M. Leedham-Green, Martin Raftery, R. Cerio, Irene M. Leigh, Peter Sasieni, Charlotte M. Proby	2012	94
9	Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England Vaccine ·David Mesher, Kate Soldan, Rebecca Howell‐Jones, Kavita Panwar, Precious Manyenga, Mark Jit, Simon Beddows, O Nöel Gill	2013	87
10	The Impact of the National HPV Vaccination Program in England Using the Bivalent HPV Vaccine: Surveillance of Type-Specific HPV in Young Females, 2010–2016 The Journal of Infectious Diseases ·David Mesher, Kavita Panwar, Sara L. Thomas, Claire Edmundson, Yoon Hong Choi, Simon Beddows, Kate Soldan	2018	71
11	Long‐term follow‐up of cervical abnormalities among women screened by HPV testing and cytology—Results from the Hammersmith study International Journal of Cancer ·Jack Cuzick, Anne Szarewski, David Mesher, Louise Cadman, Janet Austin, Karen Perryman, Linda Ho, George Terry, Peter Sasieni, Roberto Dina, William P. Soutter	2008	66
12	Alternative HER/PTEN/Akt Pathway Activation in HPV Positive and Negative Penile Carcinomas PLoS ONE ·Elzbieta Stankiewicz, David M. Prowse, Mansum Ng, Jack Cuzick, David Mesher, Frances Hiscock, Yong‐Jie Lu, N. Watkin, Catherine M. Corbishley, Wayne Lam, Daniel M. Berney	2011	64
13	Impact and Cost-effectiveness of Selective Human Papillomavirus Vaccination of Men Who Have Sex With Men Clinical Infectious Diseases ·Allen Z. Lin, Koh Jun Ong, Peter H. F. Hobbelen, Eleanor M. King, David Mesher, W. John Edmunds, Pam Sonnenberg, Richard Gilson, Irenjeet Bains, Yoon Hong Choi, Clare Tanton, Kate Soldan, Mark Jit	2016	57
14	p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis The Journal of Experimental Medicine ·Rubeta Matin, Anissa Chikh, S.L. Chong, David Mesher, Manuela Graf, Paolo Sanzà, Valentina Senatore, Maria Scatolini, Francesca Moretti, Irene M. Leigh, Charlotte M. Proby, Antonio Costanzo, Giovanna Chiorino, R. Cerio, Catherine Harwood, Daniele Bergamaschi	2013	54
15	Declining Genital Warts in Young Women in England Associated With HPV 16/18 Vaccination: An Ecological Study The Journal of Infectious Diseases ·Rebecca Howell‐Jones, Kate Soldan, Sally Wetten, David Mesher, Tim Williams, O Nöel Gill, Gwenda Hughes	2013	51
16	Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study BMJ Open ·David Mesher, Kavita Panwar, Sara L. Thomas, Simon Beddows, Kate Soldan	2016	48
17	Prospective Results of Surveillance Colonoscopy in Dominant Familial Colorectal Cancer With and Without Lynch Syndrome Gastroenterology ·Isis Dove‐Edwin, Andrea E. van der Meulen‐de Jong, J T Adams, David Mesher, Lara Lipton, Peter Sasieni, Hans F. A. Vasen, Huw Thomas	2006	45
18	Long-term follow-up of cervical disease in women screened by cytology and HPV testing: results from the HART study British Journal of Cancer ·David Mesher, Anne Szarewski, Louise Cadman, Heather Cubie, Henry C Kitchener, David Luesley, Usha Menon, G. Hulman, Mina Desai, Linda Ho, George Terry, Alistair Williams, Peter Sasieni, Jack Cuzick	2010	44
19	Predictive Value of Symptoms for Ovarian Cancer: Comparison of Symptoms Reported by Questionnaire, Interview, and General Practitioner Notes JNCI Journal of the National Cancer Institute ·Anita WW Lim, David Mesher, Aleksandra Gentry‐Maharaj, Nyaladzi Balogun, Ian Jacobs, Usha Menon, Peter Sasieni	2012	37
20	Decline in genital warts diagnoses among young women and young men since the introduction of the bivalent HPV (16/18) vaccination programme in England: an ecological analysis Sexually Transmitted Infections ·Malcolm Canvin, K Sinka, Gwenda Hughes, David Mesher	2016	37

About David Mesher

David Mesher is a scholar working on Epidemiology, Surgery, Oncology, Microbiology and Molecular Biology, having authored 52 papers that have together received 3.2k indexed citations. Recurring topics across this work include Cervical Cancer and HPV Research (33 papers), Genital Health and Disease (25 papers), Hepatitis B Virus Studies (11 papers), Reproductive tract infections research (11 papers), Molecular Biology Techniques and Applications (4 papers), Global Cancer Incidence and Screening (4 papers), Endometrial and Cervical Cancer Treatments (3 papers) and Prostate Cancer Treatment and Research (3 papers). The work is most often cited by research in Immunology and Allergy (524 citations), Epidemiology (1.4k citations), Microbiology (217 citations), Dermatology (293 citations) and Cancer Research (441 citations). David Mesher has collaborated with scholars based in United Kingdom, United States and Italy. Frequent co-authors include Peter Sasieni, Jack Cuzick, Kate Soldan, D M Parkin, Daniel M. Berney, Peter T. Scardino, Gabrielle Fisher, Louise Cadman, Alexander Gutin and Christopher S. Foster. Their work appears in journals such as British Journal of Cancer, Sexually Transmitted Infections, Vaccine, Eurosurveillance and International Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact